» Articles » PMID: 10233835

High-throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by CDNA Microarray Screening in Renal Cell Carcinoma

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1999 May 11
PMID 10233835
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Many genes and signaling pathways are involved in renal cell carcinoma (RCC) development. However, genetic tumor markers have not gained use in RCC diagnostics and prognosis prediction. Identification and evaluation of new molecular parameters are of utmost importance in cancer research and cancer treatment. Here we present a novel approach to rapidly identify clinically relevant molecular changes in cancer. To identify genes with relevance to RCC, a cDNA array analysis was first performed on 5184 cDNA clones on a filter to screen for genes with differential expression between the renal cancer cell line CRL-1933 and normal kidney tissue. There were 89 differentially expressed genes in the cancer cell line, one of them coding for vimentin, a cytoplasmic intermediate filament. In a second step, a renal cancer tissue microarray containing 532 RCC specimen was used to determine vimentin expression by immunohistochemistry. Vimentin expression was seen frequently in clear cell (51%) and papillary RCC (61%), but rarely in chromophobe RCC (4%) and oncocytomas (12%). Furthermore, vimentin expression was significantly associated with poor patient prognosis (P < 0.007) independent of grade and stage. These results obtained from minute arrayed tumor samples match well with previous findings on vimentin expression in renal tumors. It is concluded that the combination of tumor arrays and cDNA arrays is a powerful approach to rapidly identify and further evaluate genes that play a role in tumor biology.

Citing Articles

Y-chromosome loss is frequent in male renal tumors.

Buscheck F, Fraune C, Garmestani S, Simon R, Kluth M, Hube-Magg C Ann Transl Med. 2021; 9(3):209.

PMID: 33708836 PMC: 7940894. DOI: 10.21037/atm-20-3061.


Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.

Fraune C, Harms L, Buscheck F, Hoflmayer D, Tsourlakis M, Clauditz T Mol Med. 2020; 26(1):24.

PMID: 32143573 PMC: 7060561. DOI: 10.1186/s10020-020-00148-4.


Prevalence of CD8 cytotoxic lymphocytes in human neoplasms.

Blessin N, Spriestersbach P, Li W, Mandelkow T, Dum D, Simon R Cell Oncol (Dordr). 2020; 43(3):421-430.

PMID: 32141029 PMC: 7214387. DOI: 10.1007/s13402-020-00496-7.


Cancer Sample Biobanking at the Next Level: Combining Tissue With Living Cell Repositories to Promote Precision Medicine.

Bolck H, Pauli C, Gobel E, Muhlbauer K, Dettwiler S, Moch H Front Cell Dev Biol. 2019; 7:246.

PMID: 31696117 PMC: 6817465. DOI: 10.3389/fcell.2019.00246.


Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.

Chandrasekaran D, Sundaram S, N K, Padmavathi R Asian Pac J Cancer Prev. 2019; 20(10):2951-2957.

PMID: 31653140 PMC: 6982669. DOI: 10.31557/APJCP.2019.20.10.2951.


References
1.
Yao M, Shuin T, Misaki H, Kubota Y . Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 1988; 48(23):6753-7. View

2.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

3.
Seizinger B, Rouleau G, Ozelius L, Lane A, Farmer G, Lamiell J . Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988; 332(6161):268-9. DOI: 10.1038/332268a0. View

4.
Waterston R, Sulston J . The Human Genome Project: reaching the finish line. Science. 1998; 282(5386):53-4. DOI: 10.1126/science.282.5386.53. View

5.
Presti Jr J, Rao P, Chen Q, Reuter V, Li F, Fair W . Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res. 1991; 51(5):1544-52. View